Summary

Eligibility
for males ages 18-90 (full criteria)
Location
at Los Angeles 5368361, California 5332921
Dates
study started
study ends around
Principal Investigator
by Wayne Brisbane

Description

Summary

This phase II trial evaluates how well flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works to detect cancer that remains (residual) or that has come back (recurrent) after the completion of focal therapy for prostate cancer. Flotufolastat F 18 is a radioactive tracer that binds to prostate specific membrane antigen (PSMA), a protein over-expressed on prostate tumor cells. This allows for visualization of PSMA-expressing cells upon imaging. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufolastat F 18, it can be seen with PET. CT utilizes x-rays that track the body from the outside. CT images provide an exact outline of the organs and potential inflammatory tissue where it occurs in the body. The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic information obtained from the PET scan. Metabolic information means how much of the injected tracer is taken up by inflammatory tissue. Flotufolastat F 18 PET/CT imaging may be an effective and less invasive way to detect residual or recurrent disease in prostate cancer patients, compared to other methods.

Official Title

Eclipse: Flotufolastat F 18 to Determine Treatment Success Following Prostate Focal Therapy

Details

PRIMARY OBJECTIVE:

  1. To evaluate the accuracy of fluorine F 18 flotufolastat (flotufolastat F 18) compared with prostate biopsy to determine treatment success following focal therapy of the prostate.

SECONDARY OBJECTIVE:

  1. To evaluate the standard uptake volume (SUV) threshold of flotufolastat F 18 compared to Gleason score.

EXPLORATORY OBJECTIVE:

  1. To compare how flotufolastat F 18 and gallium Ga 68 gozetotide (Ga 68 PSMA 11) are distributed within the prostate in men who have previously undergone focal therapy.

OUTLINE:

Patients receive flotufolastat F-18 intravenously (IV). Then 50-100 minutes after injection, patients undergo whole-body PET/CT over 20-50 minutes. Patients then undergo PET/CT/ultrasound fusion biopsy within 3 months.

After completion of study intervention, patients are followed up at 1 month post-biopsy and then every 12 months for up to 10 years.

Keywords

Prostate Carcinoma, Prostatic Neoplasms, Magnetic Resonance Spectroscopy, Computed Tomography, Fluorine F 18 Flotufolastat, Positron Emission Tomography, Ultrasound-Guided Prostate Biopsy

Eligibility

You can join if…

Open to males ages 18-90

  • Men aged 18-90 at study enrollment
  • History of prostate cancer
  • Men who have had focal therapy (laser, cryotherapy, high-intensity focused ultrasound [HIFU], Tulsa Pro, irreversible electroporation [IRE], brachytherapy) within 6-36 months of enrollment

You CAN'T join if...

  • Contraindication to flotufolastat F 18 PET CT
  • Contraindication to ultrasound-guided prostate biopsy
  • Patients who are planned to have an x-ray contrast agent or other PET radiotracer < 24 hours prior to the PET scan
  • Patients with castrate levels of testosterone secondary to androgen deprivation therapy
  • Inability to provide written informed consent
  • Known inability to remain still and lie flat for the duration of the PET/CT (about 30 minutes)
  • Any investigational agents within 42 days prior to the day of the first dose
  • Not able to understand and to follow study instructions and requirements. This also includes the inability to complete the study imaging and or biopsy procedures due to any reason (e.g., severe claustrophobia, inability to lie still for the entire imaging time, any condition that precludes raised arms position)

Location

  • UCLA / Jonsson Comprehensive Cancer Center
    Los Angeles 5368361 California 5332921 90095 United States

Lead Scientist at UCLA

  • Wayne Brisbane
    Assistant Professor-in-Residence, Urology, Medicine. Authored (or co-authored) 51 research publications

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Jonsson Comprehensive Cancer Center
ID
NCT07185165
Phase
Phase 2 Prostate Cancer Research Study
Study Type
Interventional
Participants
Expecting 81 study participants
Last Updated